Overview

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Status:
Recruiting

Trial end date:
2021-12-21

Target enrollment:

Participant gender:

Summary

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cellestia Biotech AG